Media headlines about OpGen (NASDAQ:OPGN) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OpGen earned a news impact score of 0.21 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.0130948816257 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- OpGen (OPGN) Downgraded by Zacks Investment Research (americanbankingnews.com)
- OpGen (OPGN) and NewLink Genetics (NLNK) Head-To-Head Survey (americanbankingnews.com)
- OpGen, Inc., (NASDAQ: OPGN) – Do Technical Indicators Important For Long-Term Traders? – Stock Watch (stocksnewstimes.com)
- Zacks: Analysts Expect OpGen, Inc. (OPGN) Will Announce Quarterly Sales of $810,000.00 (americanbankingnews.com)
- Do What Insiders Does: OpGen, Inc. (OPGN), Lam Research Corporation (LRCX) – Market Movers (financialqz.com)
Shares of OpGen (OPGN) traded down $0.02 during trading on Wednesday, hitting $0.19. 1,537,500 shares of the company were exchanged, compared to its average volume of 1,543,367. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $10.78 and a price-to-earnings ratio of -0.37. OpGen has a fifty-two week low of $0.15 and a fifty-two week high of $1.85.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/10/opgen-opgn-receiving-somewhat-positive-press-coverage-analysis-shows.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.